Verrica Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary

Verrica Pharmaceuticals

09/05/2023 13:56

* Verrica Pharmaceuticals Inc  VRCA.OQ  reported a quarterly
adjusted loss of 15 cents​​ per share for the quarter ended in
March. The mean expectation of five analysts for the quarter was
for a loss of 19 cents per share.
    * Revenue fell 91.4% to $37.00 thousand from a year ago;
analysts
expected $429.33 thousand. 
    * Verrica Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 15 cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Verrica Pharmaceuticals Inc shares had risen by 1.8% this
quarter and gained 140.7% so far this year.
    * The company reported a quarterly loss of $6.59 million.
    * Wall Street's median 12-month price target for Verrica
Pharmaceuticals Inc is $11.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
9 at 12:56 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.19          -0.15          Beat
 Dec. 31 2022      -0.19          -0.14          Beat
 Sep. 30 2022      -0.11          0.03           Beat
 Jun. 30 2022      -0.32          -0.37          Missed